 The objective of this study is to estimate complete response rates for patients treated with this regimen, to assess overall response rates, event-free survival and overall survival; and to assess toxicities associated with R-CHOP GM-CSF. Patients will receive 6 to 8 cycles of R-CHOP Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone, with GM-CSF. 